Novo Nordisk, the Danish company behind two popular obesity medications, is reaping huge profits and is now responsible for most of the country’s economic growth.
Category: Diabetes
-
Wegovy, the Weight Loss Drug, Relieves Heart Failure Symptoms: Drugmaker’s Study
The drug Wegovy eased issues for people with a type of heart problem, adding to the treatment’s benefits beyond weight loss.
-
What Is ‘Food Noise’? How Ozempic Quiets Obsessive Thinking About Food
For some, it’s a startling side effect.
-
California’s Plan for Cheaper Insulin Collides With Big Pharma’s Price Cuts
The New York Times – Business:The state awarded a $50 million contract to produce less costly treatments, but moves by major suppliers might undercut the initiative before any new product emerges.
-
Sanofi Plans to Cut the Price of Insulin
The New York Times – Business:The company is the third of the three major insulin manufacturers that dominate the U.S. market to announce such a move this month.
-
Garrett Mitchell of Brewers Balances Baseball and Type 1 Diabetes
The New York Times – Sports:Baseball wants more stolen bases, and Garrett Mitchell, a rookie outfielder for the Milwaukee Brewers, is happy to oblige.
-
Eli Lilly Says It Will Cut the Price of Insulin
The New York Times – Business:The company said it would cap the monthly out-of-pocket cost of the diabetes drug at $35.
-
Those Weight Loss Drugs May Do a Number on Your Face
The New York Times – Fashion & Style:People using drugs like Ozempic are discovering an unwanted side affect: facial aging.
-
California Sues Companies Over Insulin Prices, Joining Other States
The New York Times – Business:The state is taking action against three major drug companies and the big pharmacy benefit managers in an effort to temper costs for people with diabetes.
-
Medicare Begins to Rein In Drug Costs for Older Americans
The New York Times – Business:Reforms embedded in the Inflation Reduction Act will bring savings to seniors this year. Already some lawmakers are aiming to repeal the changes.